secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001193805-22-001152
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q2 revenue $27.1M, net loss $0.82/share; ARCT-154 booster shows durable Omicron response
--------------------------------------------------------------------------------

- Revenue $27.1M (vs $2.0M Q2 2021); net loss $21.6M ($0.82/sh) improved from $54.6M ($2.07/sh) year ago.
- ARCT-154 booster: 44-fold (BA.1) and 39-fold (BA.2) neutralizing antibody GMFR at Day 91.
- ARCT-810 gets EU Orphan Medicinal Product Designation for OTC deficiency; Phase 2 study enrolling.
- ARCT-154 EUA in Vietnam delayed to Q4 2022; registrational booster study expected Q4 2022.
- Cash $283.5M at June 30, down from $370.5M at Dec 2021; expected to fund ops into late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001152/0001193805-22-001152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001152/e621864_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-001152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer